Medical Affairs and Innovative Medicinal Product Strategy Development

Area of Science:

• Pharmaceutical Development
• Oncology Therapeutics
• Clinical Strategy

Background:

• Innovative medicinal products are crucial for therapeutic advancement, particularly in oncology.
• Successful product development necessitates generating robust clinical data for regulators and healthcare providers.
• Real-world and health economic evidence are increasingly vital for pricing and reimbursement.

Purpose of the Study:

• To review challenges in developing integrated strategies for innovative medicinal products.
• To examine the roles of different pharmaceutical company functions in addressing stakeholder needs.
• To illustrate the evolving strategic leadership of Medical Affairs in product development.

Main Methods:

• Review of hurdles in integrated strategy development for innovative medicinal products.
• Analysis of functional roles within pharmaceutical companies.
• Examination of Medical Affairs' evolving strategic contributions.

Main Results:

• Integrated strategy development faces significant hurdles, especially in oncology.
• Addressing patient and stakeholder needs requires cross-functional collaboration.
• Medical Affairs is increasingly pivotal in strategic leadership.

Conclusions:

• End-to-end strategic planning is essential for innovative medicinal product success.
• Pharmaceutical companies must strategically integrate clinical, real-world, and health economic evidence.
• Medical Affairs plays a key role in navigating complex development landscapes and stakeholder engagement.